Wedbush set a $25.00 price target on XOMA (NASDAQ:XOMA) in a research note released on Tuesday morning, TipRanks reports. The firm currently has a buy rating on the biotechnology company’s stock. Wedbush also issued estimates for XOMA’s Q2 2019 earnings at ($0.59) EPS, Q3 2019 earnings at ($0.61) EPS, Q4 2019 earnings at ($0.61) EPS, FY2019 earnings at ($1.46) EPS, Q1 2020 earnings at ($0.61) EPS, Q3 2020 earnings at ($0.61) EPS, Q4 2020 earnings at ($0.54) EPS, FY2020 earnings at ($2.36) EPS, FY2021 earnings at ($2.14) EPS, FY2022 earnings at ($1.96) EPS and FY2023 earnings at ($0.63) EPS.
Other research analysts have also issued research reports about the stock. HC Wainwright set a $30.00 price objective on shares of XOMA and gave the company a buy rating in a research report on Friday, April 12th. ValuEngine raised shares of XOMA from a sell rating to a hold rating in a research report on Monday, April 1st. Finally, Zacks Investment Research raised shares of XOMA from a sell rating to a hold rating in a research report on Saturday, March 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $23.75.
XOMA stock opened at $16.18 on Tuesday. The company has a debt-to-equity ratio of 1.13, a current ratio of 7.20 and a quick ratio of 7.20. XOMA has a 52-week low of $11.02 and a 52-week high of $25.99. The stock has a market cap of $136.97 million, a price-to-earnings ratio of -10.18 and a beta of 2.38.
XOMA (NASDAQ:XOMA) last released its quarterly earnings results on Monday, May 6th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.33. XOMA had a negative net margin of 48.62% and a negative return on equity of 51.66%. The company had revenue of $8.13 million during the quarter, compared to analysts’ expectations of $3.23 million. As a group, equities analysts anticipate that XOMA will post -1.18 EPS for the current fiscal year.
In related news, major shareholder Bvf Partners L. P/Il acquired 3,797 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was acquired at an average price of $14.36 per share, with a total value of $54,524.92. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Value Fund L. P. Biotechnology purchased 27,913 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was acquired at an average cost of $14.63 per share, with a total value of $408,367.19. The disclosure for this purchase can be found here. Insiders have bought 42,010 shares of company stock valued at $612,963 in the last ninety days. 9.89% of the stock is owned by company insiders.
A number of large investors have recently bought and sold shares of XOMA. Fosun International Ltd acquired a new position in XOMA in the fourth quarter worth about $3,842,000. Opaleye Management Inc. raised its position in XOMA by 25.0% in the fourth quarter. Opaleye Management Inc. now owns 400,000 shares of the biotechnology company’s stock worth $5,060,000 after purchasing an additional 80,000 shares in the last quarter. Pennsylvania Trust Co acquired a new position in XOMA in the first quarter worth about $3,531,000. BlackRock Inc. raised its position in XOMA by 12.4% in the fourth quarter. BlackRock Inc. now owns 508,672 shares of the biotechnology company’s stock worth $6,434,000 after purchasing an additional 56,130 shares in the last quarter. Finally, Chicago Equity Partners LLC acquired a new position in XOMA in the fourth quarter worth about $501,000. 48.71% of the stock is owned by hedge funds and other institutional investors.
XOMA Company Profile
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.
Read More: Marijuana Stocks
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.